Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IdeS in sensitized CKD patients
NCT02224820Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Jun 2014
- Primary completion
- Feb 2015
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of imlifidase in chronic kidney disease (CKD), kidney transplant rejection, sponsored by Hansa Biopharma. Started Jun 2014; status: completed.
02
Drugs
imlifidase
03
Conditions
chronic kidney disease (CKD)kidney transplant rejection
Beyond the preview
Go deeper on NCT02224820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02224820.